The Health Resources and Services Administration said Wednesday it reported six drugmakers to an HHS watchdog agency for limiting product discounts in a program geared for low-income Americans, claiming the companies are running afoul of government policy.
Lilly USA LLC, Novartis Pharmacuticals, and Novo Nordisk are among the companies HRSA called out for their “continued refusal to comply” with statutory obligations under the 340B program to give discounts to covered health-care providers dispensing medications through contract pharmacy arrangements, according to letters sent to the drugmakers Wednesday.
HRSA referred the companies, along with Sanofi, AstraZeneca and United Therapeutics, to the Health ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.